DLA Piper advised Insilico Medicine, a pioneer in next-generation artificial intelligence technology for drug discovery, on a successful US$37 million Series B funding round to commercialize the validated generative chemistry and target identification technology.

Insilico Medicine has developed and validated a comprehensive drug discovery pipeline that includes a state-of-the-art molecular generator utilizing multiple proprietary generative and reinforcement learning technologies. The company identified promising targets in a variety of therapeutic modalities, including cancer, fibrosis, NASH, immunology and CNS.

Through a network of joint ventures, partnerships with early-stage biotechnology and large pharmaceutical companies, Insilico Medicine is powering the new digital-age biopharmaceutical industry. Recently, Insilico Medicine published a paper in Nature Biotechnology demonstrating the potential of deep generative chemistry for drug discovery.

The DLA Piper team was led by Hong Kong-based partner Gloria Liu and associate Misha Yang and US-based partner Matthew Gorra and associate Matt Huddle.

Insilico's press release is available here.Nature Biotechnology demonstrating the potential of deep generative chemistry for drug discovery.

The DLA Piper team was led by Hong Kong-based partner Gloria Liu and associate Misha Yang and US-based partner Matthew Gorra and associate Matt Huddle.

Insilico's press release is available here.